GLP 1 Drug Biosimilar Market Size, Share & Trends Analysis by Reference Biologic (Semaglutide Biosimilar, Liraglutide Biosimilar, Exenatide Biosimilar, Dulaglutide Biosimilar), by Formulation (Injectable Pen, Oral Tablet, Patch & Implant), by Distribution (Retail Pharmacy, Mail-Order & Specialty Pharmacy, Hospital & Clinic), and Segment Forecasts, 2026 to 2035 GLP-1 biosimilars are biological medicines developed to be highly similar in quality, safety, and efficacy to the originator GLP-1 receptor agonists, such as semaglutide, liraglutide, and dulaglutide
I recommend a 2,500-3,500 mg dosage, but some sources say 7,000 mg is the maximum safe daily dosage
Ethics declarations Conflict of interest The authors declare that they have no confict of interest
Insulin has returned to baseline, ghrelin is rising, and somatostatin tone is low
It influences menstrual cycles, bone health, mood regulation, and more